Friday 6 November 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue: +39.2%
EPS: +45.6%
Free cash flow: −58.6%
Total debt: +115.1%

Quarter to September 2026, against a year earlier

103.93 19.03 −15.48%

Follow HALO

Alert me

Market cap: $14.0B
P/E: 24.7×
Fwd P/E: 17.9×
Dividend yield: —
F-score: 5/9
Altman Z: 3.46
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Halozyme Therapeutics, Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 6, 2026 · accepted 4:11 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2025: 53 added · 21 removed · 66 modified; 5 with only figures updated; 1 moved without change

Halozyme Therapeutics, Inc. 10-Q filed Aug 6, 2026

What changed

Stockrow Weekly